News
-
-
PRESS RELEASE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health, Inc. to discuss updates on cancer supportive care portfolio in investor webcast, focusing on CTD and oral mucositis. Details on pivotal phase 3 OnTarget trial for crofelemer -
-
-
-
PRESS RELEASE
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar announces expansion of out-licensing agreement with Magdalena Biosciences for Botanical Drug Candidate targeting schizophrenia market. Company to present at Lytham Partners Spring 2024 Investor Conference -
-
PRESS RELEASE
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
Napo Pharmaceuticals announces positive results from a study on crofelemer, a plant-based prescription drug, for functional diarrhea patients, showing reduced abdominal pain and improved stool consistency -
-
PRESS RELEASE
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Jaguar Health, Inc. announces commercial launch at ASCO Annual Meeting for Gelclair, FDA-approved oral mucositis product. Focus on cancer supportive care with phase 3 OnTarget trial results impending